By end market, Sanghera said life science research tools remain the core of the business, representing 67% of revenue and growing 15% in 2025. He said applied markets now represent about one-third of revenue after increasing traction over the last two to three years, with clinical up 60% , biopharma up 30% , and applied industrial up 27% .He also pointed to the firm’s growth trajectory, stating that Oxford Nanopore has delivered 28% CAGR over the last five years and that growth in 2025 was supported by perf ...